Bharat Parenterals Ltd

Bharat Parenterals Limited has set Saturday, September 12, 2026, as the record date for determining entitlement to receive a dividend for the financial year 2025-26, subject to approval by members at the annual general meeting scheduled for 2026.

Bharat Parenterals Ltd share price slipped 1.57% to Rs 1441.7 after the company's net profit plunged by 56.37% to Rs 3.56 crore, while revenue from operations eased by 5.90% to Rs 93.74 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, gaining 4.98%. It has inched up 0.66% over last one week and heading higher by 11.72% in last one month while the market capitalization of Bharat Parenterals Ltd has softened by 2.27% and 20.64% in the same period respectively. Profit before tax (PBT) of Bharat Parenterals Ltd stood at Rs 1.49 crore in Q2 FY26, plunging by 158.43% year-on-year, and tumbling by 82.20% quarter-on-quarter. EBITDA came in at Rs 7 crore, nosediving by 41.54% YoY and tanking 279.04% sequentially. Total expenses contracted by 13.69% to Rs 93.89 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 40.5 crore, registering a fall of 21.13% YoY, while employee benefits expense was at Rs 18.84 crore, inching up 2.06% YoY. For the TTM ended FY26, revenue from operations surged 30.30% to Rs 340.38 crore, while net profit tanked by 515.60% to Rs 43.68 crore, compared to previous TTM. EBITDA soared by 4770% to Rs 8.92 crore, and PBT collapsed by 281.36% to Rs 33.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 27.25 crore in FY26, as against Rs 4.71 crore in FY25. Bharat Parenterals Ltd declined by 3% in last one year, performing in line with the benchmark BSE Sensex which has eased by 3.20% during the same period.

Bharat Parenterals Limited informed the BSE Limited that its board of directors approved the re-appointment of Mr. Hemang Shah as an Executive Director for a term of 5 consecutive years, effective July 2, 2026, to July 1, 2031, subject to shareholder approval at the upcoming Annual General Meeting.

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Net Loss of Bharat Parenterals reported to Rs 4.80 crore in the quarter ended March 2026 as against net loss of Rs 4.73 crore during the previous quarter ended March 2025. Sales declined 4.19% to Rs 99.62 crore in the quarter ended March 2026 as against Rs 103.98 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 8.19 crore in the year ended March 2026 as against net loss of Rs 12.63 crore during the previous year ended March 2025. Sales rose 1.48% to Rs 345.43 crore in the year ended March 2026 as against Rs 340.38 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales99.62103.98 -4 345.43340.38 1 OPM %-0.532.14 -4.580.79 - PBDT0.260.22 18 12.831.37 836 PBT-8.37-8.30 -1 -21.42-33.95 37 NP-4.80-4.73 -1 -8.19-12.63 35 Powered by Capital Market - Live

Bharat Parenterals announced that the Board of Directors of the Company at its meeting held on 18 May 2026, has recommended a Final Dividend of Rs.1 per share (i.e.10%), subject to the approval of the shareholders.

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 18 May 2026.

The inspection of the General Injectables Block was carried out from 13 April to 17 April 2026 and concluded on 20 April 2026. At the conclusion of the inspection, the USFDA issued five observations under a Voluntary Action Indicated (VAI) classification. The company said its subsidiary will respond within the prescribed timeline, while the final Establishment Inspection Report (EIR) is awaited. The General Injectables Block is a key facility that supports the supply of sterile injectable formulations to regulated markets, including the United States and the European Union. Commenting on the development, the company's management said, 'A surprise USFDA inspection of a sterile injectables block, concluding with a few procedural observations under a VAI classification, reflects the consistency of quality and compliance systems at Innoxel. The company continues to focus on strengthening its manufacturing and regulatory capabilities.' Bharat Parenterals as a pharmaceutical company. The Company develops anti-retroviral drugs in the form of tablets, capsules, oral liquids, eye drops, lotion, creams, and injections for the treatment of various diseases. Bharat Parenterals serves clients in India. The company reported consolidated net loss of Rs 4.39 crore in Q3 FY26 as against net loss of Rs 1.67 crore in the same quarter last year. Revenue from operations fell 9.8% YoY to Rs 65.19 crore in the quarter ended 31 December 2026. The counter added 1.31% to Rs 1,201.25 on the BSE.

Net Loss of Bharat Parenterals reported to Rs 4.39 crore in the quarter ended December 2025 as against net loss of Rs 1.67 crore during the previous quarter ended December 2024. Sales declined 9.78% to Rs 65.19 crore in the quarter ended December 2025 as against Rs 72.26 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales65.1972.26 -10 OPM %2.675.04 - PBDT0.173.25 -95 PBT-8.28-5.50 -51 NP-4.39-1.67 -163 Powered by Capital Market - Live

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live